Clinical datasets have shown that BRG1 protein levels are over-expressed in prostate cancer, in the absence of consistent significant deleterious genetic mutations evident in SMARCA4 [42, 44–46]. This evidence concerns the gene SMARCA4 and Familial prostate cancer.